CRBP — Corbus Pharmaceuticals Holdings Share News
0.000.00%
Last trade - 00:00Corbus Pharma tumbles on pricing $75 mln stock offering
Brief: Corbus Pharmaceuticals Announces Pricing Of Public Offering At $13.00 Per Share
Brief: Corbus Pharmaceuticals Announces Proposed Public Offering
Corbus Pharma tumbles on stock offering plans
U.S. STOCKS ON THE MOVE-Arm Holdings, silver miners, Zions Bancorp
U.S. STOCKS ON THE MOVE-Apple, Zoom, Arm Holdings
U.S. STOCKS ON THE MOVE-Glaukos, Reddit, Micron
U.S. STOCKS ON THE MOVE-Boeing, Planet Labs, WW International
Corbus Pharma jumps after early data for cancer therapy
U.S. STOCKS ON THE MOVE-Hershey, Eli Lilly, energy stocks
U.S. STOCKS ON THE MOVE-Aqua Metals, Corbus Pharma, Micron
Brief: FDA Grants Fast Track Status to Corbus Pharma’s Nectin 4 For Head & Neck Squamous Cell Carcinoma Treatment
Corbus Pharma rises on US FDA's second 'fast-track' tag for cancer therapy
U.S. RESEARCH ROUNDUP -ANI Pharmaceuticals, Berkshire Hathaway, Chevron
Corbus Pharmaceuticals Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Corbus Pharmaceuticals Q2 Basic EPS USD -1.44
Corbus Pharmaceuticals Holdings Inc expected to post a loss of $1.51 a share - Earnings Preview
Brief: Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion Of Phase 1 Study Of Highly Peripherally Restricted Cb1 Inverse Agonist Crb-913 For The Treatment Of Obesity
Brief: Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion Of Phase 1 Study Of Highly Peripherally Restricted Cb1 Inverse Agonist Crb-913 For The Treatment Of Obesity